The Latin America, Middle East and Africa Large Molecule Bioanalytical Testing Services Market should witness market growth of 12.5% CAGR during the forecast period (2022-2028).
Due to its target specificity, decreased toxicity, and increased potency, large-molecule therapies have become more popular recently. As a result, numerous pharmaceutical companies now provide a wide range of large-molecule medications. The usage of LC-MS has increased along with the utilization of large-molecule medicines. Although LBAs remain the industry standard for large-molecule quantification, LC-MS provides various advantages, including multiplexing and a wider linear dynamic range. The use of LC-MS for these chemicals still faces a number of difficulties, though.
Themarket for large molecule bioanalytical testing services is anticipated to rise as a result of the increasing complexity of product engineering & designs and the rising need for sophisticated and top-notch testing services. Pharmaceutical companies are under increased pressure to adopt new technologies into their services to meet consumer demand as a result of the swift improvements in healthcare. Due to faster time to market, increased regulatory scrutiny, and a higher risk of product failure, there is an increasing demand for large molecule bioanalytical testing services.
In recent years, Abu Dhabi and Dubai have both made efforts to promote medical innovation and ensure that their citizens have access to medical treatment of the highest possible standard. The Health Authority in Abu Dhabi is working to improve the quality of care, expand access to services, transition from public to private providers in a safe and efficient manner, and implement a latestfinancing model through an innovative system of mandatory health insurance. The rising investment in the healthcare sector of UAE would support the market growth in the region.
The Brazil market dominated the LAMEA Large Molecule Bioanalytical Testing Services Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $45.4 million by 2028. The Argentina market is showcasing a CAGR of 13.1% during (2022-2028). Additionally, The UAE market would register a CAGR of 12.2% during (2022-2028).
Based on End-user, the market is segmented into SMEs and Large Firms. Based on Test Type, the market is segmented into Bioavailability, ADME, PD, Bioequivalence, and Others. Based on Type, the market is segmented into ADA, Pharmacokinetics, and Others. Based on Phase, the market is segmented into Clinical and Pre-clinical (With Antibody and Without Antibody (ELISA Based Assay)). Based on Therapeutic Areas, the market is segmented into Oncology, Neurology, Infectious Diseases, Cardiology, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Laboratory Corporation Of America Holdings, IQVIA Holdings, Inc., Syneos Health, Inc., SGS S.A., Intertek Group PLC, Pace Analytical Services, LLC, ICON Plc, Charles River Laboratories International, Inc., and Thermo Fisher Scientific, Inc.
Due to its target specificity, decreased toxicity, and increased potency, large-molecule therapies have become more popular recently. As a result, numerous pharmaceutical companies now provide a wide range of large-molecule medications. The usage of LC-MS has increased along with the utilization of large-molecule medicines. Although LBAs remain the industry standard for large-molecule quantification, LC-MS provides various advantages, including multiplexing and a wider linear dynamic range. The use of LC-MS for these chemicals still faces a number of difficulties, though.
Themarket for large molecule bioanalytical testing services is anticipated to rise as a result of the increasing complexity of product engineering & designs and the rising need for sophisticated and top-notch testing services. Pharmaceutical companies are under increased pressure to adopt new technologies into their services to meet consumer demand as a result of the swift improvements in healthcare. Due to faster time to market, increased regulatory scrutiny, and a higher risk of product failure, there is an increasing demand for large molecule bioanalytical testing services.
In recent years, Abu Dhabi and Dubai have both made efforts to promote medical innovation and ensure that their citizens have access to medical treatment of the highest possible standard. The Health Authority in Abu Dhabi is working to improve the quality of care, expand access to services, transition from public to private providers in a safe and efficient manner, and implement a latestfinancing model through an innovative system of mandatory health insurance. The rising investment in the healthcare sector of UAE would support the market growth in the region.
The Brazil market dominated the LAMEA Large Molecule Bioanalytical Testing Services Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $45.4 million by 2028. The Argentina market is showcasing a CAGR of 13.1% during (2022-2028). Additionally, The UAE market would register a CAGR of 12.2% during (2022-2028).
Based on End-user, the market is segmented into SMEs and Large Firms. Based on Test Type, the market is segmented into Bioavailability, ADME, PD, Bioequivalence, and Others. Based on Type, the market is segmented into ADA, Pharmacokinetics, and Others. Based on Phase, the market is segmented into Clinical and Pre-clinical (With Antibody and Without Antibody (ELISA Based Assay)). Based on Therapeutic Areas, the market is segmented into Oncology, Neurology, Infectious Diseases, Cardiology, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Laboratory Corporation Of America Holdings, IQVIA Holdings, Inc., Syneos Health, Inc., SGS S.A., Intertek Group PLC, Pace Analytical Services, LLC, ICON Plc, Charles River Laboratories International, Inc., and Thermo Fisher Scientific, Inc.
Scope of the Study
By End-user
- SMEs
- Large Firms
By Test Type
- Bioavailability
- ADME
- PD
- Bioequivalence
- Others
By Type
- ADA
- Pharmacokinetics
- Others
By Phase
- Clinical
- Pre-clinical
- With Antibody
- Without Antibody (ELISA Based Assay)
By Therapeutic Areas
- Oncology
- Neurology
- Infectious Diseases
- Cardiology
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Laboratory Corporation Of America Holdings
- IQVIA Holdings, Inc.
- Syneos Health, Inc.
- SGS S.A.
- Intertek Group PLC
- Pace Analytical Services, LLC
- ICON Plc
- Charles River Laboratories International, Inc.
- Thermo Fisher Scientific, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 4. LAMEA Large Molecule Bioanalytical Testing Services Market by End-user
Chapter 5. LAMEA Large Molecule Bioanalytical Testing Services Market by Test Type
Chapter 6. LAMEA Large Molecule Bioanalytical Testing Services Market by Type
Chapter 7. LAMEA Large Molecule Bioanalytical Testing Services Market by Phase
Chapter 8. LAMEA Large Molecule Bioanalytical Testing Services Market by Therapeutic Areas
Chapter 9. LAMEA Large Molecule Bioanalytical Testing Services Market by Country
Chapter 10. Company Profiles
Companies Mentioned
- Laboratory Corporation Of America Holdings
- IQVIA Holdings, Inc.
- Syneos Health, Inc.
- SGS S.A.
- Intertek Group PLC
- Pace Analytical Services, LLC
- ICON Plc
- Charles River Laboratories International, Inc.
- Thermo Fisher Scientific, Inc.
Methodology
LOADING...
